HOME >> MEDICINE >> NEWS
H5N1 threat puts human flu back in spotlight

The emergence of the avian influenza virus H5N1 that is currently devastating chicken flocks in many countries and threatening to unleash a worldwide epidemic among humans has triggered a renewed interest among scientists in studying influenza A viruses, according to investigators at St. Jude Children's Research Hospital. This renewed interest could lead to new discoveries of immune system response to viruses that could lead to better drugs and vaccines, the researchers write in a review article that appears in the May issue of Nature Immunology.

"Until recently, many immunologists were relatively uninterested in studying influenza immunity because there were already effective vaccines," said Peter Doherty, Ph.D., member of the St. Jude Department of Immunology and co-recipient of the 1996 Nobel Prize for Medicine. "The current resurgence of interest in influenza immunology reflects the threat that H5N1 could evolve into a virus that spreads easily among humans. Over the years, influenza A viruses have been one of the most important models for studying how the immune system responds to viral infections. Further study of this virus and the immune response to it will no doubt help us prepare for this latest threat."

Influenza A viruses infect a wide range of animals and cause influenza outbreaks among humans. Scientists categorize influenza A viruses according to the identity of two specific proteins on their surface, HA and NA. There are 16 known subtypes of HA (H) proteins and 9 subtypes of NA (N) proteins, which are used to name the viruses, such as H5N1. The virus uses the HA protein to attach itself to a cell it is about to infect. Newly made viruses inside infected cells use NA to escape from the cell and spread.

"Studies of influenza A led to the design of Relenza and Tamiflu, two currently available anti-flu drugs," said Paul Thomas, Ph.D., a postdoctoral fellow in the St. Jude Department of Immunology and an author of the article. "B
'"/>

Contact: Kelly Perry
media@stjude.org
901-495-3306
St. Jude Children's Research Hospital
4-May-2006


Page: 1 2 3 4

Related medicine news :

1. Global warmings threat to New York region and how to avoid severe consequences
2. Sleep deprivation can threaten competent decision-making
3. Simple classification can help define and predict limb-threatening diabetic infections
4. Rapid flu tests may reduce threat of antibiotic resistance
5. Does endurance exercise promote life-threatening changes in athletes hearts?
6. Anthrax attack posed greater potential threat than thought
7. Stranger danger threat and lack of green spaces put kids off walking
8. Mental health problems threaten the knowledge economy
9. Three molecular triggers threaten leukemia patients
10. Criminalizing HIV transmission is a threat to public health, say experts
11. Predicting an answer to the threat of flooding

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: threat puts human flu back spotlight

(Date:8/1/2014)... 2014 Parker Waichman LLP, a national ... injured by defective medical devices and drugs reports that ... Ethicon surgical power morcellator devices used for the removal ... the spread of cancer associated with power morcellators, according ... 2014. , Johnson & Johnson had previously ceased ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Almost 140 ... school transportation in the United States. But ... bus-related catastrophes, Dawne Gardner, injury prevention coordinator at ... Center, said in a medical center news release. ... returning to school, it,s important for parents and ...
(Date:8/1/2014)... The evolving healthcare landscape presents ... At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor Pharmacy’s ... resources to enhance patient care and profitability. At ... issues to give independent pharmacists the tools they ... ThoughtSpot show attendance experienced a nearly 70% increase ...
(Date:8/1/2014)... DC (PRWEB) August 01, 2014 ... Thompson (D-CA), Gregg Harper (R-MS), and Peter Welch ... 5380, the Medicare Telehealth Parity Act of 2014, ... fully support this effort to improve healthcare access ... chief executive officer of ATA. "These cost-saving provisions ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 On Monday, ... California NextGen User Symposium in San Francisco, CA. Now ... at the JW Marriott Union Square hotel. , “We ... get up to speed with ACA compliance issues,” Quirk ... month. The symposium provides attendees guidance with NextGen implementation ...
Breaking Medicine News(10 mins):Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Expert Offers School Bus Safety Tips 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
(Date:8/1/2014)... 1, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Phase 3 study evaluating ISIS-SMN Rx in infants ... cause of infant mortality. Isis plans to dose the ... weeks, at which time Isis will earn an $18 ... The Phase 3 study, ENDEAR, is the first of ...
(Date:8/1/2014)... Pa. , Aug. 1, 2014 Inovio ... will host a conference call to report its second ... at 9:00 AM ET. CEO Dr. J. Joseph ... discuss second quarter earnings, provide a corporate update, and ... will include clinical development plans for VGX-3100, Inovio,s immune ...
(Date:8/1/2014)... Arena Pharmaceuticals, Inc. (NASDAQ: ... reported financial results for the second quarter ended ... continued to see encouraging advancements in the US ... in estimated total prescriptions and estimated total per ... Lief, Arena,s President and Chief Executive Officer. "Other ...
Breaking Medicine Technology:Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
Cached News: